



FOR IMMEDIATE RELEASE

Public Relations Contact:

Simona Buergi

503.245.0459

simona.buergi@hemcon.com

HemCon Medical Technologies signs exclusive partnership for the development and distribution of Synaero™ Hemostatic Gel for ENT procedures.

Introducing a novel surgical gel designed to improve patient and surgeon procedural experience.

PORTLAND, OR — September 23, 2010 — [HemCon Medical Technologies](#) (“HemCon”), a global innovative developer of advanced medical technologies and products, has recently partnered with [ENTrigue Surgical, Inc.](#) (“ENTrigue”), a leading provider of medical devices and therapies for surgeries of the Ear, Nose and Throat, to develop and distribute HemCon’s latest breakthrough product, a hemostatic surgical gel. Synaero Hemostatic Gel, based on HemCon’s [proprietary oxidized cellulose platform](#), is a hemostatic gel to be used during and after ENT surgical procedures to control bleeding, minimize edema and prevent adhesions.

ENT surgical procedures are adopting a “less-invasive” surgical approach to reduce trauma and post-surgical patient discomfort. Synaero Hemostatic Gel is designed to be easily administered endoscopically to the nasal cavity and lightly coat the mucosal tissue to control bleeding. This eliminates the need for nasal packing to control bleeding, giving surgeons clear visibility of the surgical field, allowing for more precise and faster procedures, as well as increased patient comfort.

“HemCon is proud to be leveraging one of its platform technologies and expanding its hemostatic product offerings into the ENT surgical world,” said John W Morgan, President and CEO of HemCon, “Synaero is the perfect complement to ENTrigue’s extensive line of otolaryngology products and they are a strong partner in the industry having gained the trust of clinicians with their expertise.”

The Synaero surgical gel is the first of a number of additional gel-based products that HemCon will be introducing to the surgical and broader healthcare markets.

Synaero Hemostatic Gel will be showcased during the upcoming American Academy of Otolaryngology Annual Meeting in Boston, September 26-29, 2010 in the ENTrigue booth.

About HemCon Medical Technologies Inc.

HemCon Medical Technologies is a leading global developer of advanced medical products designed to improve the standard of patient care. The company has changed military and hospital wound care best practices for hemostasis and infection control with its innovative product lines. In addition, HemCon is leading the charge to develop and license unique, life-saving medical advances including lyophilized human plasma and [nanofiber technologies](#) for wound care. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland and the Czech Republic. (www.hemcon.com).

###